Wockhardt

The nod for Zaynich—an antibiotic for treatment of complicated UTI—vindicates chairman and founder Habil Khorakiwala’s bet on antibiotic discovery and development, even as Big Pharma companies in developed economies stopped such research in favour of more lucrative drugs.

Indian markets showed volatility on May 5 amid escalating US-Iran tensions. The Nifty 50 ended up 0.36%, while the Sensex declined 0.33%. Notable gainers included CreditAccess Grameen and Wockhardt, though profit-taking led to losses in several other stocks.

Wockhardt's shares surged 12.55% to ₹ 1,604 following a profitable Q4FY26 with a net profit of ₹ 164 crore. Strong revenue growth from biotech and emerging markets fueled performance, with full-year revenue rising to ₹ 3,373 crore and EBITDA increasing by 51%.

Buy or sell: Ganesh Dongre recommends three stocks to buy on Monday — Wockhardt, LT, and HDFC Bank.

Indian drugmakers, known for their chemistry and prowess in making generics—cheaper copies of innovative drugs—for the world, have started pivoting towards innovation to stay competitive globally. Those who took the earliest, and riskiest, bets saw decisive gains this year.

Following a repo rate cut by the RBI, the Indian stock market saw renewed optimism, with Nifty 50 and Sensex gaining. Key sectors like PSU Banks and IT led the rally, despite mixed performance in broader markets.

Wockhardt's share price surged 6.5% following FDA acceptance of its New Drug Application for Zaynich, marking a significant milestone for Indian pharma. The two-day rally reached nearly 27%, reflecting renewed investor interest and highlighting India's potential in global antibiotic innovation.

Indian stocks declined on December 01 after reaching highs, influenced by a record low rupee against the dollar and foreign investor selling. The Nifty 50 fell 150 points, closing at 26,175, while the Sensex dropped 531 points to 85,625.